NCT04354727View on ClinicalTrials.gov

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 15, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

June 15, 2023

Conditions
Myelofibrosis
Interventions
DRUG

APG-1252

infusion once weekly

DRUG

Ruxolitinib

taken orally twice a day

Trial Locations (2)

77030

University of Texas MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT04354727 - A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | Biotech Hunter | Biotech Hunter